The activin E mechanism of action in obesity is having something of an early stage heyday with such players as Wave Life Sciences Ltd. and Ibio Inc. talking up data that have perked the ears of Wall Street. Read More
Neurodegeneration specialist Vesper Bio ApS has announced positive results from the phase Ib/II trial of its oral sortilin inhibitor VES-001 in frontotemporal dementia. The small study involved six participants who had not progressed to symptomatic disease but were carriers of mutations in the GRN gene that codes for progranulin, a growth factor that is essential for neuronal health. Read More
Boehringer Ingelheim GmbH has licensed an unnamed small-molecule preclinical candidate from Kyowa Kirin Co. Ltd. in the autoimmune disease space in a deal worth up to €640 million (US$739 million). Read More
Vera Therapeutics Inc.’s atacicept gained still more airtime at the Cantor Fitgerald health care conference held Sept. 4, and some on Wall Street believe the appetite for the BAFF and APRIL dual inhibitor could bode well for others in the same mechanistic space. Read More
Bowhead whales (Balaena mysticetus) live year-round in the icy or near-icy waters of the Arctic and sub-Arctic. Although they migrate with the seasonal cycles of ice formation and melting, they never reach the warmer waters visited by other large marine mammals. Their adaptation to low temperatures may have also enabled them to live longer and avoid cancer, a disease closely linked to aging. Read More
At the AACR-NCI-ORTC conference, researchers from Dewpoint Therapeutics Inc. presented advances in targeting MYC condensates, revealing a potential breakthrough strategy for treating cancers driven by MYC – a well-established oncogenic driver that is frequently overexpressed or amplified across a range of human cancers. Read More
What trends in life sciences have defined the last three decades? BioWorld Editor Nuala Moran picks monoclonal antibodies as the most significant. “They are the cornerstone around which medical biotechnology as a sector has been built.” Read More
Biopharmas raising money in public or private financings, including: Arbor, Cocrystal, DBV, Evaxion, Evommune, Helex, Mind Medicine, Oculis, Preveceutical, Savara, Tubulis, Vaxil. Read More
Clinical updates, including data readouts and publications: Argenx, Avobis, Dianthus, Innocare, Johnson & Johnson, Neutrolis, Novartis, Tectonic, Unicycive, Vor, Wave. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: 89bio, Anavex, Everest Medicines, Insmed, Novabridge, Roche, Sensei, Visara. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Amnea, Celltrion, Dewpoint, Intellia. Read More
